CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
2017 · Nature Medicine · 1,313 citations
https://doi.org/10.1038/nm.4441
T
Terry J. Fry
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
355
Papers
22.8K
Citations
61
h-index
131
i10-index
Terry J. Fry is an academic researcher from University of Colorado Anschutz Medical Campus. The author has contributed to research in topics: CAR-T cell therapy research & Immune Cell Function and Interaction & Immunotherapy and Immune Responses. The author has an h-index of 61, co-authored 302 publications.
ORCID: 0000-0001-8044-5226Papers by this author
worksConvergence of Acquired Mutations and Alternative Splicing of <i>CD19</i> Enables Resistance to CART-19 Immunotherapy
2015 · Cancer Discovery · 1,218 citations
https://doi.org/10.1158/2159-8290.cd-15-1020
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
2018 · Nature Medicine · 620 citations
https://doi.org/10.1038/s41591-018-0201-9
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
2021 · Nature Medicine · 545 citations
https://doi.org/10.1038/s41591-021-01436-0
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
2020 · Journal of Clinical Oncology · 400 citations
https://doi.org/10.1200/jco.19.03279
Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22
2018 · Molecular Therapy — Oncolytics · 271 citations
https://doi.org/10.1016/j.omto.2018.10.006
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat